Back

Filament Health ships PEX010 for Phase 2 PTSD therapy trial

Verifying
  • Filament Health shipped PEX010 to the University of Calgary for a PTSD trial.
  • The study is a Phase 2 trial of psilocybin-assisted therapy.
  • Participants are survivors of intimate partner violence, according to the announcement.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.